Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO 2023

2 - 6 Jun 2023

McCormick Place, Chicago, United States of America

Lisocabtagene maraleucel is efficacious at treating R/R chronic lymphocytic...

Dr Tanya Siddiqi - City of Hope, Duarte, USA

Lisocabtagene maraleucel is efficacious at treating R/R chronic lymphocytic leukaemia/small lymphocytic lymphoma ( Dr Tanya Siddiqi - City of Hope, Duarte, USA )

ASCO 2023: Lung cancer research highlights

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

ASCO 2023: Lung cancer research highlights ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Pembrolizumab benefits patients with brain metastases

Dr Priscilla Brastianos - Mass General Cancer Center, Boston, USA

Pembrolizumab benefits patients with brain metastases ( Dr Priscilla Brastianos - Mass General Cancer Center, Boston, USA )

FOLFOX with selective use of 5FUCRT is non-inferior to 5FUCRT for treatment of...

Dr Martin Weiser - Memorial Sloan Kettering Cancer Center, New York City, USA

FOLFOX with selective use of 5FUCRT is non-inferior to 5FUCRT for treatment of LARC prior to low anterior resection with TME ( Dr Martin Weiser - Memorial Sloan Kettering Cancer Center, New York City, USA )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic...

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City...

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

ASCO's efforts to improve global cancer care through the years

Dr Carlos Santiago Vallejos Sologuren - Oncosalud, Lima, Peru

ASCO's efforts to improve global cancer care through the years ( Dr Carlos Santiago Vallejos Sologuren - Oncosalud, Lima, Peru )

US NCI's global health initiatives at ASCO 2023

Dr Satish Gopal - National Cancer Institute, Bethesda, USA

US NCI's global health initiatives at ASCO 2023 ( Dr Satish Gopal - National Cancer Institute, Bethesda, USA )

The Lancet Commission on Women and Cancer

Dr Ophira Ginsburg - National Cancer Institute, Bethesda, USA

The Lancet Commission on Women and Cancer ( Dr Ophira Ginsburg - National Cancer Institute, Bethesda, USA )

Advancing breast cancer treatment in Uganda by improving molecular testing

Dr Jackson Orem - Uganda Cancer Institute, Kampala, Uganda

Advancing breast cancer treatment in Uganda by improving molecular testing ( Dr Jackson Orem - Uganda Cancer Institute, Kampala, Uganda )

Somatic mutation profile of breast cancer in Uganda

Dr Manoj Menon - Fred Hutchinson Cancer Center, Seattle, USA

Real-world behavioural restrictional practices of cancer patients

Dr Daniel Vorobiof - Belong.Life, New York, USA

Real-world behavioural restrictional practices of cancer patients ( Dr Daniel Vorobiof - Belong.Life, New York, USA )

KEYNOTE-716: Longer follow up supports pembrolizumab use in stage IIB/IIC...

Prof Jason J Luke - University of Pittsburgh, Pittsburgh, USA

KEYNOTE-716: Longer follow up supports pembrolizumab use in stage IIB/IIC melanoma ( Prof Jason J Luke - University of Pittsburgh, Pittsburgh, USA )

Tumour Treating Fields therapy extends OS for mNSCLC after plantinum failure

Dr Ticiana Leal - Emory University, Atlanta, USA

Tumour Treating Fields therapy extends OS for mNSCLC after plantinum failure ( Dr Ticiana Leal - Emory University, Atlanta, USA )

Primary mediastinal B-cell lymphoma: Radiotherapy superfluous post...

Prof Emanuele Zucca - Oncology Institute of Southern Switzerland, Bellinzona...

Primary mediastinal B-cell lymphoma: Radiotherapy superfluous post-chemoimmunotherapy ( Prof Emanuele Zucca - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2023: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

ASCO 2023: Latest in PARP inhibitors in prostate cancer

Prof Rana McKay, Dr Friederike Schlurmann, Prof Gunhild von Amsberg

ASCO 2023: Latest in PARP inhibitors in prostate cancer ( Prof Rana McKay, Dr Friederike Schlurmann, Prof Gunhild von Amsberg )

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine...

Dr Lin-Quan Tang - Sun Yat-sen University, Guangzhou, China

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine improves PFS in N2-3 nasopharyngeal carcinoma ( Dr Lin-Quan Tang - Sun Yat-sen University, Guangzhou, China )

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in firstline HRR mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

Axi-cel improves survival in early r/r large B-cell lymphoma

Dr Jason Westin - The University of Texas MD Anderson Cancer Center, Houston...

Axi-cel improves survival in early r/r large B-cell lymphoma ( Dr Jason Westin - The University of Texas MD Anderson Cancer Center, Houston, USA )

CDK4/6 inhibitors added to first line show no greater benefit when compared to...

Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC ( Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands )

Prognostic value of HER2-low status in breast cancer: A systematic review and...

Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis ( Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy )

Extended lymph node removal does not benefit patients with clinically localised...

Dr Seth Lerner - Baylor College of Medicine, Houston, USA

Extended lymph node removal does not benefit patients with clinically localised muscle-invasive bladder cancer ( Dr Seth Lerner - Baylor College of Medicine, Houston, USA )

Dostarlimab chemo combination for primary advanced or recurrent endometrial...

Prof Matthew Powell - Washington University School of Medicine, Missouri, USA

Dostarlimab chemo combination for primary advanced or recurrent endometrial cancer ( Prof Matthew Powell - Washington University School of Medicine, Missouri, USA )

FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial...

Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain

FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer ( Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain )

Teclistamab for RRMM: Long term follow up data from MajesTEC-1

Prof Niels Van de Donk - Amsterdam University Medical Center, Amsterdam...

Teclistamab for RRMM: Long term follow up data from MajesTEC-1 ( Prof Niels Van de Donk - Amsterdam University Medical Center, Amsterdam, Netherlands )

2L triple metronomic chemo shows more efficacy in comparison to systemic...

Dr Rushabh Kiran Kothari (PI, CRSF group) - Narayana Multispeciality Hospital...

2L triple metronomic chemo shows more efficacy in comparison to systemic therapy for head and neck cancer ( Dr Rushabh Kiran Kothari (PI, CRSF group) - Narayana Multispeciality Hospital, Ahmedabad, India )

Vaccine-immunotherapy combo for high risk melanoma: New data on distant...

Prof Muhammad Adnan Khattak - Fiona Stanley Hospital, Perth, Australia

Vaccine-immunotherapy combo for high risk melanoma: New data on distant metastasis-free survival ( Prof Muhammad Adnan Khattak - Fiona Stanley Hospital, Perth, Australia )

Next-generation selective RET inhibitor shows initial promise with RET-altered...

Prof Qing Zhou - Guangdong Provincial People’s Hospital, Guangzhou, China

Next-generation selective RET inhibitor shows initial promise with RET-altered solid tumours ( Prof Qing Zhou - Guangdong Provincial People’s Hospital, Guangzhou, China )

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses...

Dr Funda Meric-Bernstram - MD Anderson Cancer Center, Houston, USA

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses in multiple tumour types ( Dr Funda Meric-Bernstram - MD Anderson Cancer Center, Houston, USA )

Neoadjuvant chemo with mFOLFIRINOX shows survival benefit in locally advanced...

Dr Thierry Conroy - Institute Cancer De Lorraine, Nancy, France

Neoadjuvant chemo with mFOLFIRINOX shows survival benefit in locally advanced rectal cancer ( Dr Thierry Conroy - Institute Cancer De Lorraine, Nancy, France )

PHERGain trial ID's early breast cancer cases that benefit from dual HER2...

Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo ( Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain )

Osimertinib after surgery significantly improves survival in resected EGFR...

Prof Roy Herbst - Yale Cancer Center, New Haven, USA

Osimertinib after surgery significantly improves survival in resected EGFR-mutated NSCLC ( Prof Roy Herbst - Yale Cancer Center, New Haven, USA )

ASCO 2023: Breast cancer research highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2023: Breast cancer research highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Ciltacabtagene autoleucel greatly reduces risk of disease progression in...

Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA

$Ciltacabtagene autoleucel greatly reduces risk of disease progression in lenalidomide-refractory MM ( Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA )$

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Effectiveness of a cardiovascular health EHR application for cancer survivors...

Prof Kathryn Weaver - Wake Forest School of Medicine, Winston-Salem, USA

Effectiveness of a cardiovascular health EHR application for cancer survivors in community oncology practice ( Prof Kathryn Weaver - Wake Forest School of Medicine, Winston-Salem, USA )

Sintilimab plus chemo shows promise in high-risk locoregionally-advanced...

Prof Jun Ma - Sun Yat-sen University Cancer Center, Guangzhou, China

Sintilimab plus chemo shows promise in high-risk locoregionally-advanced nasopharyngeal carcinoma ( Prof Jun Ma - Sun Yat-sen University Cancer Center, Guangzhou, China )

ASCO 2023: Head and neck highlights

Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA

ASCO 2023: Head and neck highlights ( Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA )

ASCO 2023: Latest in mRCC

Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald

ASCO 2023: Latest in mRCC ( Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald )

Erdafitinib and current treatment landscape for advanced bladder cancer

Dr Yohann Loriot and Prof Arlene Siefker-Radtke

Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )

Cabozantinib with nivolumab/ipilimumab shows superior efficacy compared to...

Dr Brian Van Tine - Washington University in St Louis, St Louis, USA

Cabozantinib with nivolumab/ipilimumab shows superior efficacy compared to cabozantinib alone in soft tissue sarcoma ( Dr Brian Van Tine - Washington University in St Louis, St Louis, USA )

Baseline liquid biopsy results in treatment efficacy of FOLFIRI/cetuximab in...

Prof Sebastian Stintzing - Universitätsmedizin Berlin, Berlin, Germany

Baseline liquid biopsy results in treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC ( Prof Sebastian Stintzing - Universitätsmedizin Berlin, Berlin, Germany )

Real-world behavioural restrictional practices of cancer patients

Dr Eliya Shahar - Tel Aviv University, Tel Aviv, Israel

Real-world behavioural restrictional practices of cancer patients ( Dr Eliya Shahar - Tel Aviv University, Tel Aviv, Israel )

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment

Prof Ajay Nooka - Winship Cancer Center of Emory University, Atlanta, USA

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment ( Prof Ajay Nooka - Winship Cancer Center of Emory University, Atlanta, USA )

Pembrolizumab improves OS in firstline treatment for unresectable advanced...

Dr Penelope Bradbury - Princess Margaret Cancer Centre, Toronto, Canada

Pembrolizumab improves OS in firstline treatment for unresectable advanced pleural mesothelioma ( Dr Penelope Bradbury - Princess Margaret Cancer Centre, Toronto, Canada )

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab...

Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma ( Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA )

PHE885 CAR-T cell therapy shows high response rates for r/r multiple myeloma in...

Prof Adam Sperling - Dana-Farber Cancer Institute, Boston, USA

PHE885 CAR-T cell therapy shows high response rates for r/r multiple myeloma in phase 1 ( Prof Adam Sperling - Dana-Farber Cancer Institute, Boston, USA )

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active...

Prof Masatoshi Kudo - Kindai University, Higashiōsaka, Japan

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL ( Prof Masatoshi Kudo - Kindai University, Higashiōsaka, Japan )

Adding ribociclib to endocrine therapy shows an improvement in invasive disease...

Prof Dennis Slamon - UCLA, Los Angeles, USA

Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients ( Prof Dennis Slamon - UCLA, Los Angeles, USA )

Nine-weeks trastuzumab still effective compared with one year trastuzumab for...

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer ( Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy )

Teclistamab plus talquetamab targeting BCMA and GPRC5D shows promise in RRMM

Dr Yael Cohen - Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel

Teclistamab plus talquetamab targeting BCMA and GPRC5D shows promise in RRMM ( Dr Yael Cohen - Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel )

AI-derived digital pathology-based biomarker predicts benefit of long-term ADT...

Prof Andrew Armstrong - Duke University, Durham, USA

AI-derived digital pathology-based biomarker predicts benefit of long-term ADT with RT in localised high-risk prostate cancer ( Prof Andrew Armstrong - Duke University, Durham, USA )

Talquetamab plus daratumumab for RRMM: TRIMM-2 update

Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville...

Talquetamab plus daratumumab for RRMM: TRIMM-2 update ( Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, USA )

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment...

Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer ( Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan )

More from ecancer